PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
26.95%
R&D growth above 1.5x AXSM's 8.83%. Michael Burry would check for spending discipline.
24.63%
G&A growth while AXSM reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
3.65%
Other expenses change of 3.65% while AXSM maintains costs. Bruce Berkowitz would investigate efficiency.
26.14%
Operating expenses growth above 1.5x AXSM's 0.46%. Michael Burry would check for inefficiency.
26.14%
Total costs growth above 1.5x AXSM's 0.46%. Michael Burry would check for inefficiency.
No Data
No Data available this quarter, please select a different quarter.
3.65%
D&A growth less than half of AXSM's 11.65%. David Dodd would verify if efficiency is sustainable.
-26.20%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-26.14%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-1.70%
Other expenses reduction while AXSM shows 86.78% growth. Joel Greenblatt would examine advantage.
-26.43%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-26.43%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-26.52%
EPS decline while AXSM shows 3.13% growth. Joel Greenblatt would examine position.
-26.52%
Diluted EPS decline while AXSM shows 3.13% growth. Joel Greenblatt would examine position.
0.09%
Share count reduction exceeding 1.5x AXSM's 2.07%. David Dodd would verify capital allocation.
0.09%
Diluted share reduction exceeding 1.5x AXSM's 2.07%. David Dodd would verify capital allocation.